Seres Therapeutics Inc (MCRB) : Birchview Capital Lp added new position in Seres Therapeutics Inc during the most recent quarter end. The investment management firm now holds 5,000 shares of Seres Therapeutics Inc which is valued at $48,450 , the company said in a statement filed on Aug 9, 2016 with the SEC.Seres Therapeutics Inc makes up approximately 0.03% of Birchview Capital Lp’s portfolio.
Other Hedge Funds, Including , Ubs Asset Management Americas Inc boosted its stake in MCRB in the latest quarter, The investment management firm added 55,772 additional shares and now holds a total of 144,323 shares of Seres Therapeutics Inc which is valued at $1,404,263.Jennison Associates boosted its stake in MCRB in the latest quarter, The investment management firm added 269,382 additional shares and now holds a total of 670,639 shares of Seres Therapeutics Inc which is valued at $6,451,547. Seres Therapeutics Inc makes up approx 0.01% of Jennison Associates’s portfolio. Columbus Circle Investors added MCRB to its portfolio by purchasing 367,502 company shares during the most recent quarter which is valued at $3,535,369. Seres Therapeutics Inc makes up approx 0.03% of Columbus Circle Investors’s portfolio. Quantbot Technologies Lp added MCRB to its portfolio by purchasing 700 company shares during the most recent quarter which is valued at $6,734.
Seres Therapeutics Inc opened for trading at $11.08 and hit $11.89 on the upside on Wednesday, eventually ending the session at $11.42, with a gain of 2.51% or 0.28 points. The heightened volatility saw the trading volume jump to 11,96,745 shares. Company has a market cap of $460 M.
On the company’s financial health, Seres Therapeutics Inc reported $-0.70 EPS for the quarter, missing the analyst consensus estimate by $ -0.25 based on the information available during the earnings call on Aug 11, 2016. Analyst had a consensus of $-0.45. The company had revenue of $3.00 million for the quarter, compared to analysts expectations of $5.89 million. During the same quarter in the previous year, the company posted $-1.45 EPS.
Many Wall Street Analysts have commented on Seres Therapeutics Inc. Shares were Reiterated by FBR Capital on Aug 12, 2016 to “Outperform” and Lowered the Price Target to $ 23 from a previous price target of $43 .Seres Therapeutics Inc was Downgraded by BofA/Merrill to ” Neutral” on Aug 1, 2016. Shares were Reiterated by H.C. Wainwright on Aug 1, 2016 to “Buy” and Lowered the Price Target to $ 15 from a previous price target of $50 .
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.